Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06849518

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Ballad Health · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCirculogene liquid biopsy testingA Circulogene liquid biopsy testing for plasma NGS ctDNA and plasma cfRNA PD-L1 expression.

Timeline

Start date
2025-02-11
Primary completion
2026-03-01
Completion
2027-03-01
First posted
2025-02-27
Last updated
2025-02-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06849518. Inclusion in this directory is not an endorsement.

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer (NCT06849518) · Clinical Trials Directory